Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma

Judson, Ian; Radford, John; Harris, Maggie A; Blay, Jean‐Yves; Hoesel, Q. van; Cesne, Axel Le; Oosterom, Allan Van; Clemons, Mark; Kamby, Claus; Hermans, C; Whittaker, J; Paola, Eugenio Donato Di; Verweij, Jaap; Nielsen, Søren

doi:10.1016/s0959-8049(01)00050-8

Cited by 336 publications

(164 citation statements)

References 13 publications

Supporting

Mentioning

152

Contrasting

Unclassified

Order By: Relevance

“…Studies using pegylated liposomal doxorubicin (PLD) in the treatment of sarcomas at other sites have shown variable results in response rates with improved toxicity profile and at least equivalent activity in comparison to doxorubicin [12–14]. However, angiosarcomas in particular have unique histopathological and biologic features compared to other soft tissue sarcomas.…”

Section: Discussionmentioning

confidence: 99%

Primary Cardiac Angiosarcoma

Kodali

Seetharaman²

2006

Sarcoma

View full text Add to dashboard Cite

Primary cardiac sarcoma is a rare clinical entity, with an incidence of 0.0001% in collected autopsy series. The majority of the literature describes a uniformly dismal prognosis with a median survival of only 6 months for these aggressive tumors. Standard surgery, adjuvant chemotherapy, and radiotherapy have been consistently unsuccessful. Early heart transplantation and novel radiation therapy approaches may offer a survival benefit in nonmetastatic tumors, but up to 80% of the patients present with systemic metastasis at diagnosis. Though several chemotherapeutic regimens have been tried, the role of chemotherapy is not well established and outcome data available is minimal. Liposomal doxorubicin (PLD) has been shown to be useful in the treatment of soft tissue sarcomas, and our case supports its use in cardiac angiosarcoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Primary Cardiac Angiosarcoma

Kodali

Seetharaman²

2006

Sarcoma

View full text Add to dashboard Cite

show abstract

“…Caelyx ® was reported to be less toxic in the clinic than the unencapsulated form (Judson et al, 2001;O'Brien et al, 2004;Porter & Rifkin, 2007); when used to treat malignant glioma, stabilization of the disease (reduction of tumor volume of < 50% or a < 25% increase in tumor volume for more than 8 weeks) was observed (Fabel et al, 2001;Hau et al, 2004). An orthotopic GBM pre-clinical study showed anti-vascular activity of doxorubicin when encapsulated in LNPs, and these effects were not observed with the free form of the drug or in normal brain tissue (Zhou et al, 2002).…”

Section: Lipid Nanoparticle Delivery Systemsmentioning

confidence: 99%

The Potential and Challenges of siRNA-Based Targeted Therapy for Treatment of Patients with Glioblastoma

Verreault¹,

Yip²,

Toyota³

et al. 2012

Novel Therapeutic Concepts in Targeting Glioma

View full text Add to dashboard Cite

“…To reduce cardiotoxicity, doxorubicin can be encased in liposomes, reducing the amount of free doxorubicin (Cattel et al 2003). Liposomal doxorubicin treatment of soft tissue sarcomas has equivalent activity but fewer adverse effects relative to free doxorubicin, and thus it is included in the current National Comprehensive Cancer Network guidelines for the treatment of soft tissue sarcomas (Judson et al 2001). However, the lipid envelope increases doxorubicin absorption and retention by the skin.…”

Section: Prognosis and Treatmentmentioning

confidence: 99%

“…However, the lipid envelope increases doxorubicin absorption and retention by the skin. Side effects of liposomal doxorubicin may include dermal rash or sores on the palms and soles of the feet called palmar-plantar erythodysesthesia (Judson et al 2001;Lorusso et al 2007). The latter can be severe enough to require a dosage decrease, treatment interruption, or termination of treatment (Lorusso et al 2007).…”

Section: Prognosis and Treatmentmentioning

confidence: 99%